Pacira Drug Promotion Suit Settled With Broad Concessions From FDA
This article was originally published in The Gray Sheet
Executive Summary
The agency will formally rescind Exparel warning letter and expand labeling to clarify that pain drug is not limited to any specific surgery. The drug case has been closely watched for implications on FDA's oversight of off-label communications for both drugs and devices.
You may also be interested in...
FDA Seeks To Resolve First Amendment Suit By Pacira
Judge extends date for agency response to firm's complaint as parties continue settlement talks; case reveals two chinks in FDA’s off-label regulatory regime armor, former FDA advisor says.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.